Literature DB >> 108720

Effects of physostigmine, scopolamine, and mecamylamine on the sleeping time induced by ketamine in the rat.

E M Figallo, L B Wingard.   

Abstract

Male Sprague-Dawley rats weighing 116--241 g were injected i.p. with ketamine hydrochloride, 80 mg per kilo of body weight. Immediately after loss of righting reflex, scopolamine, physostigmine, and mecamylamine were administered i.p. to different groups of rats. Control animals received sterile saline by the same route. The ketamine-induced sleeping time was significantly prolonged by physostigmine and scopolamine, but not by mecamylamine. After the delayed injection of physostigmine, the ketamine sleeping time was longer. These results, although too preliminary for a mechanistic interpretation, suggest that multiple neurotransmitter systems, probably including the cholinergic system, are involved in the mechanism of action of ketamine-induced narcosis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108720     DOI: 10.1007/bf00426811

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

Review 1.  Pharmacological implications of brain acetylcholine turnover measurements in rat brain nuclei.

Authors:  D L Cheney; E Costa
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Psychotomimetic drugs as anticholinergic agents. II. Quantum-mechanical study of molecular interaction potentials of 1-cyclohexylpiperidine derivatives with the cholinergic receptor.

Authors:  H Weinstein; S Maayani; S Srebrenik; S Cohen; M Sokolovsky
Journal:  Mol Pharmacol       Date:  1973-11       Impact factor: 4.436

3.  Distribution in the brain and metabolism of ketamine in the rat after intravenous administration.

Authors:  M L Cohen; S L Chan; W L Way; A J Trevor
Journal:  Anesthesiology       Date:  1973-10       Impact factor: 7.892

4.  [Studies on the metabolism of tropane alkaloids. 8. Chemical analysis of (-)-scopolamine metabolism in several mammals].

Authors:  G Werner; K H Schmidt
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1968-06

5.  The cataleptic state induced by ketamine: a review of the neuropharmacology of anesthesia.

Authors:  W D Winters; T Ferrar-Allado; C Guzman-Flores; M Alcaraz
Journal:  Neuropharmacology       Date:  1972-05       Impact factor: 5.250

Review 6.  Behavioral and electroencephalographic effects of atropine and related compounds.

Authors:  V G Longo
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

7.  Reversal of central anticholinergic syndrome in man by physostigmine.

Authors:  R C Duvoisin; R Katz
Journal:  JAMA       Date:  1968-11-25       Impact factor: 56.272

8.  The treatment of scopolamine-induced delirium with physostigmine.

Authors:  E B Crowell; J S Ketchum
Journal:  Clin Pharmacol Ther       Date:  1967 May-Jun       Impact factor: 6.875

9.  Amnesic properties of scopolamine and brain acetylcholine in the rat.

Authors:  A Pazzagli; G Pepeu
Journal:  Int J Neuropharmacol       Date:  1965-09

10.  Acetylcholine concentrations and turnover in rat brain structures during anesthesia with halothane, enflurane, and ketamine.

Authors:  S H Ngai; D L Cheney; A D Finck
Journal:  Anesthesiology       Date:  1978-01       Impact factor: 7.892

View more
  3 in total

1.  Antagonistic effect of physostigmine on ketamine-induced anesthesia.

Authors:  M Mimura; A Namiki; R Kishi; T Ikeda; H Miyake
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Interactions of cholinesterase inhibitors and glucocorticoids with ketamine and pentobarbitone-induced general anaesthesia in the rat: possible effects on central cholinergic activity.

Authors:  R S Leeuwin; J K van der Wal; W Spanjer
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

3.  Evaluation of antianxiety and sedative effects of essential oil of Ducrosia anethifolia in mice.

Authors:  Valiollah Hajhashemi; Mohammad Rabbani; Alireza Ghanadi; Elahe Davari
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.